Imricor Reports 2025 Net Loss of $25.3M on Early Commercialisation and Regulatory Progress

SEC Form 10 Amendment Clears Regulatory Hurdle

Imricor Medical Systems (ASX:IMR) has filed an amendment to its Form 10 Registration Statement with the US Securities and Exchange Commission (SEC), ironing out minor edits from the SEC’s review. This voluntary filing, which is not tied to a US IPO or stock exchange listing, is expected to become effective on 17 May 2026, marking a key step in Imricor’s transition to a US reporting company.

The update comes as Imricor continues to build regulatory momentum in the US market, having secured FDA 510(k) clearance for its NorthStar Mapping System and Vision-MR Diagnostic Catheter in January 2026. These clearances follow a period of intense clinical trial activity, including the VISABL-AFL and VISABL-VT studies targeting US approval for its Vision-MR Ablation Catheter and expanded indications.

Early Commercialisation Stage Sees Revenue Drop Amid Clinical Focus

Despite these regulatory advances, Imricor’s 2025 financials reveal the challenges of early-stage commercialisation. Revenue fell 70% to $292,000, primarily due to lower sales volumes of third-party equipment and consumables, as several European sites enrolled patients in clinical trials rather than commercial procedures. This dynamic was highlighted in the company’s earlier report showing a 69.5% revenue drop amid its strategic FDA push.

Operating expenses climbed 34% to $23.1 million, reflecting investments in sales and marketing team expansion, regulatory submissions, and clinical trial activities. The net loss narrowed to $25.3 million from $29.7 million in 2024, helped by a reduction in non-cash fair value expenses on financial instruments. Imricor’s cash and marketable securities stood at $40.8 million at year-end, bolstered by a $42.8 million capital raise in March 2025.

Clinical Trials and Market Expansion Drive Next Steps

Imricor’s ongoing VISABL-AFL trial aims to secure FDA approval for Type I atrial flutter treatment, with enrollment expected to complete in mid-2026. The VISABL-VT trial, focused on ventricular tachycardia, has already achieved several world-first milestones including MRI-guided ablations in complex patients. Non-roll-in patient enrollment is set to begin in Q3 2026, with regulatory approval timelines hinging on trial outcomes.

The company’s commercial strategy targets high-volume academic and specialized arrhythmia centers initially in Europe and the Middle East, with US market entry anticipated in early 2027 following FDA approvals. Imricor’s hybrid sales and distribution model combines direct sales teams in the US and Europe with exclusive distributors in the Middle East, notably Al Faisaliah in Saudi Arabia and East Agency in Qatar.

Imricor’s intellectual property portfolio is extensive, with over 90 patents and applications protecting its MRI-compatible cardiac ablation technology globally. The company also maintains strategic partnerships with major MRI vendors Siemens, Philips, and GE, enabling integration of its products into existing MRI systems and facilitating turnkey iCMR labs.

Governance, Related Party Interests, and Risks

The company’s board includes four independent directors and a nominee from K.A.H.R. Foundation, a major shareholder and holder of convertible notes. The Foundation’s nominee, Dr Jeffrey Leighton, joined the board in July 2024. Related party transactions, including convertible notes and warrants issued to K.A.H.R. Foundation, are disclosed with fair value adjustments impacting earnings.

Imricor’s risk disclosures underscore the uncertainties inherent in regulatory approvals, market adoption of novel MRI-guided ablation technology, competitive pressures from established fluoroscopy and emerging pulsed field ablation technologies, and financial sustainability given ongoing losses and capital needs.

Investors should note the company’s ongoing efforts to scale manufacturing, expand sales capabilities, and secure reimbursement coverage, all critical to transitioning from early commercialisation to profitability.

This update follows Imricor’s recent FDA pediatric label expansion submission for the NorthStar Mapping System, targeting over 250 US children’s hospitals, signaling a broader US commercial rollout strategy.